Meropenem Venus Pharma (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic lysis and rapid bactericidal activity against a broad range of aerobic and anaerobic organisms, including many resistant strains.

The dosage of Meropenem Venus Pharma is individualized by the prescribing clinician according to the type and severity of infection, patient weight, renal function, and susceptibility data. Typical adult regimens range from 500 mg to 2 g administered intravenously every 8 hours, but exact dosing must be determined by a qualified prescriber.

Safety data for meropenem in pregnancy and lactation are limited. Animal studies have not shown teratogenic effects, but human data are insufficient to rule out risk. Consequently, meropenem should be used during pregnancy or breastfeeding only if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Meropenem shares the broad‑spectrum activity typical of carbapenems such as imipenem‑cilastatin and ertapenem, but it offers enhanced stability against many β‑lactamases and a slightly broader anaerobic coverage. Its dosing interval (often every 8 hours) may differ, and it is not co‑formulated with a renal protective agent, unlike imipenem‑cilastatin. Choice of agent depends on local resistance patterns, infection site, and patient factors.

Meropenem Venus Pharma must be stored refrigerated at 2 °C to 8 °C. Keep the vials in the original packaging, protect from light, and avoid freezing or shaking. Once reconstituted, the solution should be used within the time frame specified in the product labeling and stored at controlled room temperature if required for short periods.

Meropenem Venus Pharma is supplied as a sterile powder for injection and is administered intravenously. The powder is reconstituted with the appropriate diluent, then further diluted in compatible IV fluids such as 5 % dextrose or normal saline. Infusion is typically given over 15–30 minutes, but infusion time may be adjusted based on patient tolerance and clinical protocol.

The most serious adverse reactions to meropenem include seizure activity, especially in patients with pre‑existing CNS disorders or renal impairment, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Clinicians should monitor neurological status, renal function, and signs of allergic response throughout therapy and discontinue the drug if serious events occur.

Meropenem is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Patients with a history of severe allergic reactions to β‑lactam antibiotics should avoid its use. Additionally, caution is advised for patients with uncontrolled epilepsy or severe renal dysfunction, where alternative agents may be preferred.